Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 16/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.89 |
| ▸ | TSHR | P16473 | 8/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.56 |
| ▸ | USP2 | O75604 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17608851 | 0.99 | CYP2D6 (0.87) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL17609032 | 0.94 | CYP2D6 (0.84) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL323730 | 0.87 | CYP2D6 (0.76) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL17608892 | 0.85 | CYP2D6 (0.84) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL1426593 | 0.85 | CYP2D6 (0.84) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL13818182 | 0.85 | CYP2D6 (1.00) | CYP2D6CYP3A4TSHRCYP2C19CYP2C9 | |
| Hydrochloric Acid SCHEMBL3013775 | 0.84 | CYP2D6 (0.82) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL14027003 | 0.83 | TSHR (0.73) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL4875408 | 0.81 | CYP2D6 (0.76) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 | |
| SCHEMBL4292159 | 0.80 | CYP2D6 (0.76) | CYP2D6CYP3A4TSHRCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908897-B2 | Spirocyclic derivatives | CHRONOS THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| US-20170253615-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2017-09-07 | — | — | US | disclosed |
| WO-2016042452-A1 | Spirocyclic derivatives | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8563539-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2013-10-22 | — | — | US | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| EP-1960382-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | CYP2D6 2833/4885CYP3A4 2881/4885TSHR 4578/4885 |
| US-20170253615-A1 | Spirocyclic derivatives | SLC6A3, SLC10A1, ABCB11 | CYP2D6 372/4885CYP3A4 1808/4885TSHR 340/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | CYP2D6 3061/4885CYP3A4 2763/4885TSHR 2915/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | CYP2D6 2783/4885CYP3A4 2848/4885TSHR 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.